Chargement en cours...
Population pharmacokinetics of PF-05280014 (a trastuzumab biosimilar) and reference trastuzumab (Herceptin(®)) in patients with HER2-positive metastatic breast cancer
PURPOSE: PF-05280014 is a biosimilar to trastuzumab (Herceptin(®)). Following demonstration of pharmacokinetic (PK) similarity in healthy volunteers, a comparative clinical study in patients with HER2-positive metastatic breast cancer (mBC) compared the efficacy, safety and immunogenicity of PF-0528...
Enregistré dans:
| Publié dans: | Cancer Chemother Pharmacol |
|---|---|
| Auteurs principaux: | , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
Springer Berlin Heidelberg
2019
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6586910/ https://ncbi.nlm.nih.gov/pubmed/31053945 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00280-019-03850-1 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|